Arkema stock gains as Q2 2026 earnings and voting rights update support outlook

Arkema stock is drawing investor attention as Q2 2026 earnings show higher EBITDA and adjusted net profit, while a fresh voting rights statement as of August 31, 2026 clarifies the French specialty chemicals group’s capital structure in the Euronext Paris and CAC Next 20 context.

Arkema stock (ISIN FR0010313833) is attracting investors as the French specialty chemicals group reported higher earnings in the second quarter of 2026, with adjusted net profit rising to EUR 129 million from EUR 120 million in Q2 2025 and Q2 2026 EBITDA increasing to EUR 391 million from EUR 364 million a year earlier, according to a sector summary dated September 3, 2026.

Q2 2026 earnings show profit growth

According to a European chemicals results overview published on September 3, 2026, Arkema generated Q2 2026 sales of EUR 2,428,000,000, up from EUR 2,396,000,000 in Q2 2025, an increase of about 1.3 percent that highlights modest top line growth in a demanding macro environment, as reported by ad-hoc-news.de.

The same overview states that Arkema’s Q2 2026 EBITDA came in at EUR 391,000,000 compared with EUR 364,000,000 in Q2 2025, meaning earnings before interest, taxes, depreciation and amortization expanded by roughly 7.4 percent year on year as profitability benefited from Specialty Materials and disciplined cost management.

Adjusted net profit for Q2 2026 reached EUR 129,000,000, versus EUR 120,000,000 in the prior year quarter, implying growth of around 7.5 percent and signaling that Arkema is successfully converting revenue and EBITDA improvements into bottom line gains in its specialty chemicals portfolio.

Guidance and capital structure context

An earnings call summary for Q1 2026 cited in the same coverage indicates that Arkema delivered revenues of EUR 2,200,000,000 in the first quarter of 2026, down 8.4 percent year on year, while Q1 2026 EBITDA totaled EUR 283,000,000, up 14 percent sequentially but lower than in the prior year period, underscoring that the company’s earnings momentum strengthened as it moved into Q2 2026.

Despite the year on year decline in Q1 2026 revenue, Arkema’s management confirmed guidance for slight full year 2026 EBITDA growth at constant exchange rates, pointing to sequential improvement in Specialty Materials and ongoing cost control as key levers for margin resilience in a softer volume environment.

Beyond operating performance, Arkema’s capital structure remains clearly defined. A statement about the number of shares and voting rights published on September 3, 2026 shows that as of August 31, 2026 the company had 76,060,831 shares outstanding and a total of 95,375,484 voting rights including shares held by the company, while voting rights excluding treasury shares stood at 94,865,641, according to a notice carried by Business Wire.

This combination of growing EBITDA and adjusted net profit in Q2 2026 with a stable share base and detailed voting rights disclosure offers investors a clearer basis for assessing Arkema’s leverage and governance profile as they compare the stock with other specialty chemicals names listed on Euronext Paris.

CAC Next 20 and European peer perspective

The Q2 2026 figures place Arkema among French mid to large cap companies that are constituents of the CAC Next 20 index, an index often viewed as a pipeline for future additions to the CAC 40 benchmark, as highlighted by the corporate profile in the September 3, 2026 sector summary on ad-hoc-news.de.

For investors comparing European chemicals exposure, Arkema’s modest 1.3 percent revenue increase alongside a roughly 7.4 percent gain in EBITDA in Q2 2026 shows that the group is prioritizing margin quality over aggressive volume-driven growth, a pattern that can be relevant when benchmarking against peers such as Clariant, which offers a DACH sector comparison for specialty materials and performance additives.

In addition, the detailed voting rights data as of August 31, 2026 complements this sector view by confirming that Arkema’s free float and governance structure are in line with expectations for a widely held French listed specialty chemicals company, which can matter for index trackers and institutional investors focusing on stewardship metrics.

Representative product: mining additives

Arkema’s operations span adhesives, coatings and advanced materials, but a representative product area for investors is its mining additives portfolio, where the group supplies sulfhydryl collectors under the ArrMaz brand to support copper and cobalt ore processing, as described in a sulfhydryl collector market overview dated September 3, 2026.

In that overview, Arkema is identified as a large multinational specialty chemicals provider headquartered in Colombes, France, with its mining additives forming part of a broader Specialty Materials offering aimed at critical minerals, an end market whose demand for performance additives can underpin medium term growth in specialized formulations.

Arkema stock and current market perspective

Arkema stock is listed on Euronext Paris under the ticker AKE and ISIN FR0010313833, with investors focusing on how the Q2 2026 earnings momentum and confirmed full year 2026 EBITDA guidance translate into share performance relative to the CAC Next 20 index and European chemicals peers as of early September 2026.

The latest figures on Q2 2026 revenue rising to EUR 2,428,000,000, EBITDA climbing to EUR 391,000,000 and adjusted net profit improving to EUR 129,000,000, together with the August 31, 2026 share and voting rights data stating 76,060,831 shares and 95,375,484 voting rights including treasury shares, provide a quantitative basis for assessing Arkema’s valuation and balance sheet in the current market environment.

Arkema stock fact box

• Company: Arkema S.A.
• ISIN: FR0010313833
• Ticker: AKE
• Trading venue: Euronext Paris
• Sector / Industry: Specialty chemicals
• Index membership: CAC Next 20